Source: Allergan DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will…...
Cigna, Express Scripts shareholders approve $67B deal
Source: FierceHealthcare Shareholders with both Cigna and Express Scripts voted to approve the insurer’s $67 billion acquisition of the PBM, the companies announced on Friday. The shareholder approval marks an important hurdle in finalizing the deal and follows several weeks in which Cigna tussled with activist investor Carl Icahn, momentarily…...
Dermavant inks $330M deal for GSK’s phase 3-ready psoriasis drug
Source: FierceBiotech A new CSO isn't all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British drugmaker's dermatology drug tapinarof in a deal worth up to £250 million ($330 million). The asset is poised to enter phase 3 in psoriasis and atopic dermatitis and is also…...
Amazon to buy PillPack in potentially disruptive drug retail push
Source: Reuters Amazon.com Inc said on Thursday it would buy small online pharmacy PillPack, a move that will put the world’s biggest online retailer in direct competition with drugstore chains, drug distributors and pharmacy benefit managers. The deal’s potential to disrupt major players across the drug supply chain nationwide prompted…...